Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 cAd3 Marburg vaccine trial in healthy adults
PACTR202306534727467Phase 2Not yet recruiting
- Sponsor
- Sabin Vaccine Institute
- Start
- Sep 2023
- Countries
- 2
01
Overview
Phase 2, randomised trial in Marburg virus disease (MVD) (2 arms), sponsored by Sabin Vaccine Institute. Primary endpoint: Safety and tolerability. Planned start Sep 2023; status: not yet recruiting.
02
Conditions
Marburg virus disease (MVD)
Beyond the preview
Go deeper on PACTR202306534727467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202306534727467.